#JPM21: Avidity CSO Art Levin runs full speed to the clinic with 'dream' antibody oligonucleotide conjugate therapy
Art Levin is living his “scientist’s dream come true.”
The Avidity Biosciences CSO set out years ago to build a new class of oligonucleotide-based therapies for severe muscle diseases, like Duchenne muscular dystrophy (DMD) and myotonic dystrophy (DM1) — rare, genetic disorders that causes progressive muscle weakness.
“As you might imagine, in the 15 or 16 years I’ve been working on this, I’ve seen boys go from being toddlers, to being wheelchair-bound, or even ventilator-bound,” he said, referring to DMD. “It would be really … a scientific dream of mine to actually make a difference for this patient population.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
